LGD-3303 – Kodiac biolabs

Plain-language summaryIntrigue 42 / 100

LGD-3303 is a less-well-known SARM from Ligand Pharmaceuticals, developed as a candidate for osteoporosis. In ovariectomized rat models (the standard postmenopausal-bone preclinical model) it produced bone anabolic effects comparable to or exceeding raloxifene, with relatively favorable bone-versus-muscle selectivity. Phase 1 human studies were conducted but the compound did not advance further, and full clinical results were never published. It is occasionally encountered as a research chemical but is much less common than ostarine or ligandrol. Limited human data and an inactive development program limit clinical relevance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

32/100

Bone-selective SARM with a stalled development record and thin independent evidence base

Look, LGD-3303 deserves a fair read before you dismiss it, but that fair read lands it pretty low on the priority list. It’s a non-steroidal SARM with a genuinely interesting tissue selectivity profile: preclinical data in ovariectomized rats showed bone anabolic activity on par with or exceeding raloxifene, while prostate-sparing effects were better than what you’d expect from a compound this anabolically active. That tissue dissociation story is the most interesting thing LGD-3303 has going for it. Most SARMs optimize for muscle. This one was explicitly engineered for bone. Thats a real, if narrow, research angle.

Here’s the thing though. Ligand ran a Phase 1 and then stopped. The compound never moved to Phase 2, and there’s no public explanation for why. That’s a ceiling, not a floor. It means the entire human-relevant evidence base is a pharmacokinetics read from a Phase 1 trial that wasn’t followed up. We’re not saying the compound failed on efficacy in humans, we’re saying we simply dont know, and the developer apparently decided the answer wasn’t worth finding out. That’s a worse position than compounds with failed Phase 2s, because at least failed Phase 2s tell you something.

The preclinical literature itself is fine but narrow. Rodent osteoporosis models are a legitimate research tool, and the OVX rat work for LGD-3303 is competent. But the independent replication is basically absent. This is a Ligand-generated compound with a Ligand-generated evidence base. The SARM class broadly has had the same problem: most of the interesting early preclinical work comes from the groups that developed the compounds. Multi-lab independent confirmation for LGD-3303 specifically is sparse.

Where we think LGD-3303 retains real, if limited, utility is as a bench-level probe for investigators studying AR conformation and tissue-selective signaling in bone biology. Its selectivity profile is genuinely distinct from RAD-140 or LGD-4033, and if your research question is about how AR agonist conformation drives tissue preference, having LGD-3303 in the panel alongside ostarine and RAD-140 gives you a data point you can’t get otherwise. The 24-hour plasma half-life is also convenient for rodent dosing protocols. That’s not nothing.

But honestly, if you’re not specifically interrogating bone-selective AR pharmacology, theres no compelling reason to put LGD-3303 on your bench over better-evidenced SARMs. The novelty is modest, the human signal is almost absent, and the development history doesn’t inspire confidence. We score it where the evidence puts it: a niche probe with a specific but narrow use case, not a compound to prioritize in a general research program.

Novelty: 28
Mechanism promise: 38
In-category differentiation: 35
Evidence quality: 28
Translational signal: 22
Research bench value: 38

Rationale LGD-3303 scores low primarily because Phase 1 completion without Phase 2 advancement is a genuine negative translational signal, and the evidence base is almost entirely from Ligand’s own development program. The bone-over-muscle selectivity is a real and mechanistically interesting differentiator within the SARM class, but it isn’t compelling enough to offset thin replication and a dead development program.

Selective androgen receptor modulator

A non-steroidal SARM developed by Ligand Pharmaceuticals for osteoporosis; less studied than ligandrol.

Abstract

LGD-3303 (9-chloro-2-ethyl-1-methyl-3-(2,2,2-trifluoroethyl)-3H-pyrrolo[3,2-f]quinolin-7(6H)-one; molecular formula C16H14ClF3N2O; molecular weight 342.74) is a non-steroidal SARM developed by Ligand Pharmaceuticals as a candidate for osteoporosis. Preclinical studies in ovariectomized rats demonstrated strong bone anabolic activity comparable to or exceeding raloxifene at appropriate doses, with reduced prostate effects. Tissue selectivity profile favors bone over muscle within the SARM class. Phase 1 human studies were conducted but the compound did not advance to phase 2. The compound retains research utility for bone-focused SARM pharmacology and is occasionally used recreationally. Plasma half-life is approximately 24 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-269Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.